Truist analyst Joon Lee lowered the firm’s price target on Crispr Therapeutics to $100 from $120 and keeps a Buy rating on the shares after its Q2 results. Casgevy launch is progressing with over 35 of 75 target ATCs activated, up from 25 in Q1, but with vein-to-vein time at over 6 months, the firm is moderating its assumptions, the analyst tells investors in a research note. To truly unlock full commercial potential, a gentler, less toxic, fertility sparing, conditioning regimen may be needed, Truist added, also cutting its FY24 EPS view by 36c to ($4.82) and its FY25 view by 51c ($5.37).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Mid-Cap Stocks: CRSP Offers Tremendous Growth Potential With Inherent Risks
- Crispr Therapeutics price target lowered to $60 from $66 at RBC Capital
- Crispr Therapeutics price target lowered to $59 from $60 at Stifel
- Crispr Therapeutics price target lowered to $59 from $67 at Barclays
- Crispr Therapeutics price target lowered to $94 from $112 at Chardan